[go: up one dir, main page]

BRPI0815550A2 - Método para estabilizar fenilefrina - Google Patents

Método para estabilizar fenilefrina

Info

Publication number
BRPI0815550A2
BRPI0815550A2 BRPI0815550-0A2A BRPI0815550A BRPI0815550A2 BR PI0815550 A2 BRPI0815550 A2 BR PI0815550A2 BR PI0815550 A BRPI0815550 A BR PI0815550A BR PI0815550 A2 BRPI0815550 A2 BR PI0815550A2
Authority
BR
Brazil
Prior art keywords
phenilefrine
stabilizing
stabilizing phenilefrine
Prior art date
Application number
BRPI0815550-0A2A
Other languages
English (en)
Inventor
Hugh Huang
Jonathan Zeszotarski
Anthony Bean
William Michael Nichols
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of BRPI0815550A2 publication Critical patent/BRPI0815550A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0815550-0A2A 2007-08-13 2008-07-30 Método para estabilizar fenilefrina BRPI0815550A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/891,693 US8323695B2 (en) 2007-08-13 2007-08-13 Method for stabilizing phenylephrine
PCT/US2008/071510 WO2009023434A2 (en) 2007-08-13 2008-07-30 Method for stabilizing phenylephrine

Publications (1)

Publication Number Publication Date
BRPI0815550A2 true BRPI0815550A2 (pt) 2015-02-18

Family

ID=40260786

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815550-0A2A BRPI0815550A2 (pt) 2007-08-13 2008-07-30 Método para estabilizar fenilefrina

Country Status (8)

Country Link
US (1) US8323695B2 (pt)
EP (2) EP2246045B1 (pt)
CN (1) CN101820862B (pt)
AU (1) AU2008287177B2 (pt)
BR (1) BRPI0815550A2 (pt)
CA (1) CA2695759C (pt)
RU (1) RU2010109366A (pt)
WO (1) WO2009023434A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315291A1 (en) * 2004-12-13 2006-06-22 Mcneil-Ppc, Inc. Compositions and methods for stabilizing active pharmaceutical ingredients
US9078824B2 (en) * 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US10130627B2 (en) 2008-12-19 2018-11-20 GlaxoSmithKine Consumer Healthcare S.A. Phenylephrine formulations with improved stability
WO2010080339A1 (en) * 2008-12-19 2010-07-15 Novartis Ag Phenylephrine formulations with improved stability
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
US20140271892A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Phenylephrine resinate particles having good auc
DK3010484T3 (da) * 2013-06-17 2019-08-05 Fremont Group Ltd Injicerbare farmaceutiske præparater omfattende adrenalin og citronsyre
WO2015051264A1 (en) 2013-10-03 2015-04-09 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof
WO2015137829A1 (en) * 2014-03-12 2015-09-17 Angeles Relinda G Stable and palatable liquid pharmaceutical composition of phenylephrine and a maleate salt of an antihistamine
CN104983732B (zh) * 2015-05-28 2018-05-04 华润三九医药股份有限公司 一种布洛肾素那敏片及其制备方法
CN104922124B (zh) * 2015-05-28 2017-06-30 华润三九医药股份有限公司 一种肾素那敏片及其制备方法
EP3952899A1 (en) 2019-04-11 2022-02-16 R.P. Scherer Technologies, LLC Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN110302149A (zh) * 2019-08-07 2019-10-08 北京博达绿洲医药科技研究有限公司 一种适合4-11岁儿童服用抗感冒药物及其制备方法
CN111214449B (zh) * 2020-03-02 2021-09-07 广东彼迪药业有限公司 一种盐酸西替利嗪片剂及其制备方法
CN111714503A (zh) * 2020-05-15 2020-09-29 北京博达绿洲医药科技研究有限公司 包含重酒石酸去氧肾上腺素和阿司匹林的复方固体组合物及其制剂和用途
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
CN112472677A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1084864A (en) 1964-02-06 1967-09-27 Merck & Co Inc Medicated lozenges
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
ATE481090T1 (de) * 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6500463B1 (en) * 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
GB0028575D0 (en) 2000-11-23 2001-01-10 Elan Corp Plc Oral pharmaceutical compositions containing cyclodextrins
NZ530889A (en) * 2001-07-31 2005-03-24 Wyeth Corp Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
US20080050422A1 (en) 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
US20040132827A1 (en) 2001-10-26 2004-07-08 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
AU2003219348A1 (en) 2002-04-22 2003-11-03 Adcock Ingram Intellectual Property (Proprietary) Limited Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
JP4473539B2 (ja) * 2003-08-12 2010-06-02 エスエス製薬株式会社 医薬組成物
JP2005062094A (ja) 2003-08-19 2005-03-10 Mitsubishi Heavy Ind Ltd 長尺低エネルギ電子線照射装置
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20060004094A1 (en) * 2004-07-02 2006-01-05 Agisim Gary R Composition and method for treating hemorrhoids and/or anorectal disorders
AU2005315291A1 (en) * 2004-12-13 2006-06-22 Mcneil-Ppc, Inc. Compositions and methods for stabilizing active pharmaceutical ingredients
BRPI0519212A2 (pt) 2004-12-23 2009-01-06 Mcneil Ppc Inc composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial
NZ573173A (en) * 2006-06-01 2012-03-30 Msd Consumer Care Inc Phenylephrine pharmaceutical formulation and compositions for colonic absorption

Also Published As

Publication number Publication date
WO2009023434A2 (en) 2009-02-19
CA2695759C (en) 2015-11-10
AU2008287177B2 (en) 2013-03-28
WO2009023434A3 (en) 2009-04-09
EP2190414B1 (en) 2014-12-17
EP2246045A1 (en) 2010-11-03
CN101820862A (zh) 2010-09-01
AU2008287177A1 (en) 2009-02-19
EP2190414A2 (en) 2010-06-02
CN101820862B (zh) 2012-07-25
US20090047343A1 (en) 2009-02-19
RU2010109366A (ru) 2011-09-20
CA2695759A1 (en) 2009-02-19
EP2246045B1 (en) 2012-06-27
US8323695B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
BRPI0819127A2 (pt) Método para cimentar.
BRPI0919116A2 (pt) método
DK2313489T3 (da) Fremstillingsmetode
BRPI0810710A2 (pt) Método para estabilização de uma proteína.
BRPI0811786A2 (pt) Acionador para inalador dosimetrado
BRPI0922490A2 (pt) Método para produção de beta-santaleno
BRPI0813858A2 (pt) Método para produzir peptídeo
BRPI0812741A2 (pt) Método para separação de glóbulos
BRPI0809678A2 (pt) Métodos
BRPI0810416A2 (pt) Método de hidroformação
BRPI0916597A2 (pt) Método
BRPI0915106A2 (pt) benzimidazóis substituídos para neurofibromatose
BRPI0814011A2 (pt) método para preparação de biobutanol
PT2214358T (pt) Método para o mapeamento de túneis
BRPI1007891A2 (pt) métodos para perfurar material
ES1064958Y (es) Soporte para mechero
ES1064720Y (es) Guia para persiana
BRPI0906523A2 (pt) Método para conferir sabor
ES1065835Y (es) Caperuza para cetreria
BRPI0816658A2 (pt) Método para produzir n-metacriloil-4-ciano-3-trifluorometilanilina
ES1066267Y (es) Soporte para protesis

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]